企業プロフィール

Veru Inc 株価・ニュース・カタリスト

ティッカー:: VERU
取引所:: NASDAQ
セクター:: Biopharma
所在地:: United States

株価パフォーマンス

2.63 USD (-3.66%)

終値

最終更新: 2026年8月17日

37.7M USD

時価総額

株価変動の要因

As of Aug 17, 2026, VERU closed down 3.66% at $2.63. No new same-company headline was identified in the current news window.

企業概要

Cardiometabolic and Inflammation Company

Veru develops late-stage small molecules for cardiometabolic and inflammatory diseases.

Enobosarm

Enobosarm is an oral selective androgen receptor modulator being evaluated to preserve lean mass, physical function, and bone health during GLP-1-driven weight loss in older adults with obesity.

PLATEAU Study

The Phase 2b PLATEAU study combines enobosarm with semaglutide and measures body composition, weight, function, and safety.

今後のカタリスト

Interim lean-mass and fat-mass analysis from the Phase 2b PLATEAU study in the first quarter of 2027.
Final topline results from the Phase 2b PLATEAU study in the fourth quarter of 2027.